Johnson & Johnson brings 3 presentations to BPI 2026 in Boston. Its program concerns antibody product quality and cell line strategy. Sessions examine galactosylation of the antibody Fc region and host cell protein challenges in antibody manufacturing, and ask whether cell lines for multispecifics and gene therapy are still built with monoclonal antibody thinking.
| Organization | BPI 2026 Attendance |
|---|---|
Johnson & Johnson New Brunswick, New Jersey | 1 Senior Scientist · 1 Principal Scientist · 1 Director, Cell Engineering & Analytical Sciences |
Global healthcare company whose Innovative Medicine segment develops, manufactures and markets pharmaceuticals including antibodies and cell therapies. | Talk Wed Sep 23 9:00am–9:30am Talk Thu Sep 24 2:15pm–2:45pm |
Instantly find 20 buyers from Johnson & Johnson
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by Informa Connect or the BioProcess International Conference & Exhibition. Submit a correction